Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 10/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP4Z1 | Q86W10 | 5/20 | 1.00 |
| ▸ | CYP4F11 | Q9HBI6 | 2/20 | 1.00 |
| ▸ | CYP4F12 | Q9HCS2 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580552 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL4269302 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL16079472 | 0.78 | CYP3A4 (0.64) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL11420876 | 0.71 | CYP2C9 (0.58) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL1019112 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL6896659 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL5720593 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL5720594 | 0.71 | CYP3A4 (0.55) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL5838115 | 0.69 | SKP2 (0.68) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 | |
| SCHEMBL2475751 | 0.69 | NPC1 (0.62) | CYP2C9CYP2D6CYP3A4CYP4Z1CYP4F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061450-B1 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MEDICAL COLLEGE WISCONSIN INC (US) | 2017-04-19 | — | — | EP | claimed |
| US-9480664-B2 | Compositions and methods for treating cancer | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2016-11-01 | — | — | US | claimed |
| US-9295667-B2 | Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A inhibitor as an active ingredient | KOREA BASIC SCIENCE INSTITUTE (KR) | 2016-03-29 | — | — | US | claimed |
| US-8846764-B2 | Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20140275198-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES OR FATTY LIVER CONTAINING A CYP4A INHIBITOR AS AN ACTIVE INGREDIENT | KOREA BASIC SCIENCE INSTITUTE (KR) | 2014-09-18 | — | — | US | claimed |
| EP-1682153-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW Research Foundation, Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050124618-A1 | Methods of modulating angiogenesis and cancer cell proliferation | HENRY FORD HEALTH SYSTEM | 2005-06-09 | — | — | US | claimed |
| WO-2005046658-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW RESEARCH FOUNDATION, INC. (US) | 2005-05-26 | — | — | WO | claimed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12479821-B2 | Quinoline compound and use thereof | MBD Co., Ltd. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| EP-3900725-B1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | KOREA BASIC SCIENCE INST (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-1682153-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW Research Foundation, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050153871-A1 | Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular disease | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050124618-A1 | Methods of modulating angiogenesis and cancer cell proliferation | HENRY FORD HEALTH SYSTEM | 2005-06-09 | — | — | US | disclosed |
| WO-2005046658-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW RESEARCH FOUNDATION, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1330240-A2 | USE OF 20-HETE SYNTHESIZING ENZYME INHIBITORS AS THERAPY FOR CEREBRAL VASCULAR DISEASES | MCW Research Foundation (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036108-A2 | USE OF 20-HETE SYNTHESIZING ENZYME INHIBITORS AS THERAPY FOR CEREBRAL VASCULAR DISEASES | MCW RESEARCH FOUNDATION, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP2C9 871/4885CYP2D6 349/4885CYP3A4 1288/4885 |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | CYP2C9 49/4885CYP2D6 45/4885CYP3A4 3/4885 |
| US-12479821-B2 | Quinoline compound and use thereof | CYP4A11, CYP7A1, CYP4B1 | CYP2C9 198/4885CYP2D6 87/4885CYP3A4 9/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | CYP2C9 59/4885CYP2D6 41/4885CYP3A4 6/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP2C9 871/4885CYP2D6 349/4885CYP3A4 1288/4885 |
| US-20140275198-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES OR FATTY LIVER CONTAINING A CYP4A INHIBITOR AS AN ACTIVE INGREDIENT | CYP4A11, CYP4A22, CYP7A1 | CYP2C9 86/4885CYP2D6 105/4885CYP3A4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.